Hysterectomy

Global Surgical Robots Market Forecast Report to 2030 - Partner & Customer Ecosystem Competitive Index & Regional Footprints - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 24, 2024
Biotechnology, Surgery, Health, Robotics, Technology, Artificial intelligence, CMR Surgical, Renishaw plc, Infection, Research, Bypass surgery, Hospital, Intuitive Surgical, Partner, Others, Surgeon, Stryker Corporation, AI, Government, Appendectomy, Algorithm, Risk, Johnson & Johnson, USD, Pain, Medtronic, Hysterectomy, Instrument, Machine learning, Colectomy, Region, Prostatectomy, Siemens Healthineers, Growth, Medical device

The "Global Surgical Robots Market 2030 by Product Type, Application, End-user, and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Surgical Robots Market 2030 by Product Type, Application, End-user, and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints" report has been added to ResearchAndMarkets.com's offering.
  • Major players Surgical Robots Market include: Stryker Corporation, Medrobotics, Smith & Nephew, TransEnterix Surgical, Inc., Renishaw plc., Intuitive Surgical, Medtronic, THINK Surgical, Inc., Zimmer Biomet, Asensus Surgical, Siemens Healthineers, CMR Surgical, Johnson & Johnson, Renishaw Plc.
  • The demand for these computer-assisted surgical systems is substantial, being utilized in open surgeries, laparoscopic procedures, and flexible endoscopic procedures.
  • One key trend in the Surgical Robots Market is the integration of artificial intelligence (AI) and machine learning (ML) technologies into surgical robotic systems.

Global Surgical Robots Market Report 2024 - Projected at USD 7.3 Billion by 2030: Integration of AI & High Demand for Minimally Invasive Surgeries Propel North America to the Forefront

Retrieved on: 
Wednesday, January 24, 2024
Artificial intelligence, CMR Surgical, Renishaw plc, Infection, Research, Bypass surgery, Hospital, Intuitive Surgical, Partner, Others, Surgeon, Stryker Corporation, AI, Government, Appendectomy, Algorithm, Risk, Johnson & Johnson, USD, Pain, Medtronic, Hysterectomy, Instrument, Machine learning, Colectomy, Region, Prostatectomy, Siemens Healthineers, Growth, Medical device

Major players Surgical Robots Market include: Stryker Corporation, Medrobotics, Smith & Nephew, TransEnterix Surgical, Inc., Renishaw plc., Intuitive Surgical, Medtronic, THINK Surgical, Inc., Zimmer Biomet, Asensus Surgical, Siemens Healthineers, CMR Surgical, Johnson & Johnson, Renishaw Plc.

Key Points: 
  • Major players Surgical Robots Market include: Stryker Corporation, Medrobotics, Smith & Nephew, TransEnterix Surgical, Inc., Renishaw plc., Intuitive Surgical, Medtronic, THINK Surgical, Inc., Zimmer Biomet, Asensus Surgical, Siemens Healthineers, CMR Surgical, Johnson & Johnson, Renishaw Plc.
  • The use of medical robotic systems has become widespread in the fields of gynaecology and cosmetology, particularly for minimally invasive surgeries.
  • The demand for these computer-assisted surgical systems is substantial, being utilized in open surgeries, laparoscopic procedures, and flexible endoscopic procedures.
  • One key trend in the Surgical Robots Market is the integration of artificial intelligence (AI) and machine learning (ML) technologies into surgical robotic systems.

Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women

Retrieved on: 
Thursday, January 11, 2024
Oncology, Health, Consumer, Women, Surgery, Health Technology, General Health, Hologic, AUB, Woman, Patient, Uterine fibroid, MD, Pelvic pain, Life, Multimedia, Fibroid, HOLX, Pain, Better, Bleeding, Hysterectomy, Fatigue, Marketing, Physician, Birth control

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™.
  • Launching in New York, Los Angeles, Atlanta and Detroit, the campaign seeks to increase awareness about daily quality-of-life challenges such as heavy and disruptive periods, pelvic pain and fibroids, while also educating women about available treatment options.
  • The campaign hub, BetterIsPossible.com , offers downloadable materials such as a period symptom quiz, discussion guides and information about potential treatment options.
  • For more information about how Hologic is supporting physicians to discuss hysterectomy-alternative treatment options, visit gynsurgicalsolutions.com/hcp/for-medical-professionals/
    For more information about the Better is Possible campaign and to access educational resources, visit BetterIsPossible.com .

Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids

Retrieved on: 
Tuesday, January 2, 2024
Category 1, Constipation, Commercial, Hysterectomy, Woman, Uterine fibroid, Language, Place of birth, Literature, ACOG, Sonata, American Medical Association, Medicare, Obstetrics, Fibroid, American College, Uterus, Current Procedural Terminology, CPT, Patient, Pressure

The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.

Key Points: 
  • The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.
  • Commenting on the new CPT code, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “We are very pleased that the AMA has established a new Category I code that applies to our Sonata® Procedure for the treatment of uterine fibroids.
  • The code is a critical milestone for the broader adoption of the technology to treat uterine fibroids in the United States.
  • Fibroids are treated from inside the uterus, so the Sonata Procedure requires no incisions, no tissue is surgically removed, and the uterus is preserved.

City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research

Retrieved on: 
Friday, December 8, 2023
Research, Women, Genetics, Health, Consumer, Pharmaceutical, General Health, Science, Oncology, BRCA1, Perception, Woman, WHI, Prevalence, City, Incidence, Menopause, Risk, Breast cancer, Cardiovascular disease, Cancer, Patient, Multimedia, History, Hispanic, INSPIRE, Hysterectomy, Genetic testing, Data collection, BRCA2, Hormone replacement therapy, Prognosis, Standard of care, Ovarian cancer, Diagnosis, African Americans, Uterus, Progesterone, BRCA, Physician, Mutation, Medical imaging, Birth control, Hope

City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 5 to 9 in San Antonio, Texas.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 5 to 9 in San Antonio, Texas.
  • (Photo: Business Wire)
    Each year, about 10,000 physicians, scientists and other health care professionals attend the annual conference, which examines new breast cancer research and helps guide treatment of patients nationwide.
  • It is the largest and most prestigious scientific gathering on breast cancer research.
  • Women who have BRCA1 tend to have more aggressive breast cancers and the mutation can also cause ovarian cancer.

Memphis Vascular Center Opens New Outpatient Diagnostic and Treatment Facility

Retrieved on: 
Thursday, November 30, 2023
General Health, Other Health, Health, Radiology, Oncology, Hysterectomy, Uterus, Vascular disease, Risk, Fungal infection, MVC, Woman, Fibroid, Patient, Blood, Cancer, Medical imaging

Memphis Vascular Center (MVC), a medical practice specializing in vascular and interventional radiology, has opened a new outpatient center to serve patients throughout the Memphis area.

Key Points: 
  • Memphis Vascular Center (MVC), a medical practice specializing in vascular and interventional radiology, has opened a new outpatient center to serve patients throughout the Memphis area.
  • The center’s doctors provide high quality diagnostic and minimally invasive treatment for vascular disease, cancer and other health conditions.
  • “Thanks to our new center, patients can be treated in an outpatient setting, where convenience and exceptional care are the priority.
  • Other benefits include a lower risk of hospital-acquired infections and lower overall cost.”
    The new center houses a combination of state-of-the-art diagnostic imaging equipment and treatment rooms.

New Case Study Analysis on the Benefits of Vaginal Hysterectomy vs. Laparoscopic Hysterectomy featuring SRC-Accredited Master Surgeon Dr. Greg Marchand

Retrieved on: 
Tuesday, December 12, 2023
Hysterectomy, Pain, Obstetrics and gynaecology, Surgeon, Meta-analysis, Woman, Gynaecology, Systematic review, Patient, SRC, Scar, Birth control

RALEIGH, N.C., Dec. 12, 2023 /PRNewswire/ -- SRC-Accredited Master Surgeon in Minimally Invasive Gynecology Dr. Greg Marchand recently co-authored a large-scale systematic review and meta-analysis, " Vaginal Hysterectomy Compared With Laparoscopic Hysterectomy in Benign Gynecological Conditions ," published in Obstetrics & Gynecology .

Key Points: 
  • RALEIGH, N.C., Dec. 12, 2023 /PRNewswire/ -- SRC-Accredited Master Surgeon in Minimally Invasive Gynecology Dr. Greg Marchand recently co-authored a large-scale systematic review and meta-analysis, " Vaginal Hysterectomy Compared With Laparoscopic Hysterectomy in Benign Gynecological Conditions ," published in Obstetrics & Gynecology .
  • The analysis explores the benefits of minimally invasive vaginal hysterectomy versus laparoscopic abdominal hysterectomy.
  • Twenty-three case articles that met strict criteria were analyzed by a panel of providers, including Dr. Marchand, director of the Marchand Institute for Minimally Invasive Surgery in Mesa, Arizona.
  • The study found that while abdominal hysterectomy patients reported less pain than vaginal hysterectomy patients on the day of surgery, vaginal hysterectomies resulted in shorter operation times, faster patient recovery, less blood loss and scarring.

HSS Presents New Reproductive Health Research at the ACR Convergence 2023

Retrieved on: 
Tuesday, November 14, 2023
Knowledge, Woman, Cervical cancer, Contraindication, Patient, Rheumatoid arthritis, Documentation, SLE, Infertility, Diagnosis, Rheumatology, Rheumatism, Fertility, Prevalence, Menopause, Vaccination, Cryopreservation, Flare, DSM-IV codes, Birth, Connective tissue, Hospital for Special Surgery, Doctor of Public Health, Female, Fetus, Smoking, Senior counsel, RD, SAN, Menstrual cycle, Weill Cornell Medicine, Immunosuppression, Risk, History, Hysterectomy, Inflammatory arthritis, Lupus, HSS, PAP, Fertilisation, OOC, Research, Human papillomavirus infection, Ageing, Scleroderma, Systemic scleroderma, Vaccine, American College, American College of Rheumatology, COVID-19, Fertility preservation, MPH, ACR, HPV, Hospital, Birth control, Nursing, Food delivery, MD

Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.

Key Points: 
  • Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.
  • This study surveyed women of reproductive age with systemic rheumatic disease about their use of contraceptives.
  • Data were collected on 249 women with reproductive capacity, including 147 with inflammatory arthritis and 102 with lupus-like disorders.
  • This study used data from the electronic health record of patients diagnosed with a rheumatic disease in adolescence, seen at HSS, to look at factors associated with HPV vaccination.

Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure

Retrieved on: 
Thursday, November 2, 2023
Hysterectomy, MVM, General partnership, Uterine fibroid, Woman, Investment, Patient, Acceleration, Pharmaceutical industry

The round was led by existing Gynesonics investors Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.

Key Points: 
  • The round was led by existing Gynesonics investors Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.
  • “Gynesonics continues to lay a strong foundation for success, having achieved a number of important commercial milestones in the most recent quarters,” said Joyce Erony, General Partner, Amzak Health.
  • “The Company is very well positioned to continue the acceleration of its growth going forward.
  • MVM is glad to support Gynesonics in offering a uterus-preserving, incisionless alternative to hysterectomy and myomectomy.”
    “This funding will enable Gynesonics to continue to expand commercial operations and provide millions of patients suffering from symptomatic fibroids a safe and efficacious minimally invasive treatment,” said Skip Baldino, President and CEO of Gynesonics.

Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure

Retrieved on: 
Thursday, November 2, 2023
Hysterectomy, MVM, General partnership, Uterine fibroid, Woman, Investment, Patient, Acceleration, Cryptocurrency, Pharmaceutical industry

The round was led by existing Gynesonics investors Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.

Key Points: 
  • The round was led by existing Gynesonics investors Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.
  • “Gynesonics continues to lay a strong foundation for success, having achieved a number of important commercial milestones in the most recent quarters,” said Joyce Erony, General Partner, Amzak Ventures.
  • “The Company is very well positioned to continue the acceleration of its growth going forward.
  • MVM is glad to support Gynesonics in offering a uterus-preserving, incisionless alternative to hysterectomy and myomectomy.”
    “This funding will enable Gynesonics to continue to expand commercial operations and provide millions of patients suffering from symptomatic fibroids a safe and efficacious minimally invasive treatment,” said Skip Baldino, President and CEO of Gynesonics.